Hepatitis C New Zealand

March 8, 2010

Hepatitis C New Zealand Blog March 2010

Hepatitis C conference  Whakatane 2010

Past Failures and New Solutions in Hepatitis B and C control in New Zealand and the Asia Pacific region
Tariana Turia - NZ Viral Hepatitis Conference 2010

Tuatahi me mihi atu ki te mana whenua. Tena koutou o Mataatua waka. Tena hoki koutou o nga mata waka kua whakarauika nei i raro i te karanga o te ra

Tena koutou i runga i te rangimarie. Tena koutou i runga i nga maharatanga mo ratou kua wheturangitia.

No reira, tena tatou katoa

I want to thank the Hepatitis Foundation of New Zealand for the honour of being invited to open this third New Zealand Viral Hepatitis Conference.

I acknowledge the local people of this rohe, and I thank them for their generosity in hosting us here in Whakatane.

I extend a particular welcome to our international guests:

* Professor Mitchell Shiffman from the United States;
* Professor Andrew Lloyd from Australia;
* Dr Morris Sherman from Canada and
* Dr James Fung from Hong Kong.

While both Hepatitis B and C viruses are notifiable conditions under the Health Act, it is only cases of acute infection which require to be notified to the Medical Officer of Health.

Alongside with the lack of awareness that comes from being asymptomatic; people with hepatitis may experience stigma and discrimination which compounds the problems of living with the virus.

So the call to do better is an important one.

We must continue to raise awareness, leading to increased testing and diagnosis.
Well spoken words from Tariana Turia

Life after liver transplant

Hi, This is my first post of my Video Diary following my Liver Transplant and my continued fight against my Hepatitis C infection/virus. Just a quick one to saay hello - I’ve never done video before and so let’s hope for all our sakes that I get better at it soon!

Please check out my blog: http://www.ianquill.blogspot.com - Thanks for watching…. Ian Quill

Hepatitis C Drug Trails NZ March 2010

Four drug trials for Hepatitis C in New Zealand at the moment (March 2010)
http://clinicaltrials.gov/ct2/results?term=hepatitis+c+New+zealand&recr=Open
1, TMC435-TiDP16-C206: A Safety and Efficacy Study in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

2,  A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

3, Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive

4, Antiviral Activity of AZD7295 in HCV Carriers

Doctor  Magdalena Harris

thesis is available online now

Negotiating the pull of the normal: embodied narratives of living with hepatitis C in New Zealand and Australia (2010)
Harris, Magdalena , National Centre In HIV Social Research, Faculty Of Arts & Social Sciences, UNSW
My status as a person living with hepatitis C informed all aspects of this research project; I therefore also include my own experiences, foregrounding researcher reflexivity and the co-constructed nature of the interview process.

“ My aims are both practical and theoretical. On a practical level I explore the experiences of people living with hepatitis C in order to inform recommendations for policy, research and practice, while also working to elucidate and employ an approach that allows for an analysis of the ill body as a lived experiencing agent, located in a substantive web of connections whereby discourse, corporeality and sociality, inform and mediate one another. To this end I employ a “political phenomenology” influenced by phenomenological and poststructuralist theoretical approaches. The central, previously under-researched, issues that arose in participants’ narratives structure the chapter outline, with results chapters focusing on participants’ experiences of diagnosis, living with hepatitis C, stigma, support group membership, alcohol use, and hepatitis C treatment.

For many participants, it was found that living with hepatitis C was a liminal experience where distinctions between what it was to be healthy or ill were not clear-cut. Indeed, many of the participants’ narratives exposed the inadequacy of Western binary categorisations to speak to their experiences of living with hepatitis C. Throughout this thesis it can be seen that the meanings that participants ascribed to health, illness, and their hepatitis C were fluid and contextual, informed by the interplay of corporeality and discourse. From this interplay comes the ability to speak into the gaps of dominant discourses, creating the potential for the disruption, or subtle realignment, of normative ways of knowing. “
Download  your copy here
http://unsworks.unsw.edu.au/vital/access/manager/Repository/unsworks:7899

Congratulations  Dr Harris from all your peers.

The best of health
www.hcv.org.nz

December 14, 2009

Hepatitis C New Zealand laboratory notification

Strategic Directions for Hepatitis C improving access to and uptake of hepatitis C treatment services.

One of the key points of this unreleased document, (Rumour has it will be never released as it involves the New Zealand Ministry of Health  acknowledging they have a major problem and actually doing something about it , i.e. spending money.)

Key action area 4 Improving knowledge about HCV prevalence in the New Zealand population and within sub groups.

HCV is a notifiable disease in New Zealand, but is really notified.

In Australia they operate a national registry for HCV the register gathers notifications from care providers and reference laboratories. Reference laboratory notifications in Australia make up 90% of all notifications.

It seems logical then to introduce  a laboratory notification system here in New Zealand to give accurate information on the number of people of people in New Zealand with HCV similar to what already occurs for HIV and aids notifications.

It seem a fundamental first step to dealing with any contagious disease is to effectively measure it’s prevalence we hope 2010 is the year the New Zealand  Ministry of health make this a priority.

Small chance of being diagnosed and treated for hepatitis C in New Zealand

I had an interesting conversation the other day.  Bob was saying how great he felt after completing Hepatitis C Treatment a couple of years back. We agreed the treatment sucked but the change in your health after completing successful treatment can be miraculous, he claimed to feel like he was 16 again, although I don’t feel that good the energy levels were back and I do feel healthy.

Bob claimed he could get up in the early morning climb a mountain shoot a deer, gut it out and climb back down with a dead deer on his back and then go and work all day. Me I’m just happy not to be constantly exhausted all the time.

Small chance of being diagnosed and treated for hepatitis C in New Zealand. Based on the fact that nationally approximately 300 people are treated per year and 50,000 are estimated to have hepatitis C. Made me feel lucky and thankful.

It always amazes just how wide spread people with Hepatitis C are and how little they talk about it because of the perceived stigma of the disease.

Some don’t seek hepatitis C treatment

NEW YORK, Nov. 10 (UPI) — U.S. researchers say patients with more difficult to treat forms of hepatitis C are half as likely to get treatment as those with easier to treat forms.

Dr. Thomas McGinn of Mount Sinai School of Medicine said the researchers also found marital status also affected whether patients chose treatment for hepatitis C.

“Overall, in general only about 30 percent of hepatitis C patients choose to initiate treatment for the disease,” the senior author said in a statement. “It’s a huge problem that needs to be addressed. This study confirms that genotype is a major barrier to treatment. We hope these findings will lead to changes in how physicians approach patient care in a way that increases the rate of treatment initiation.”

In this study, of the 168 treatment-eligible patients, 41 began treatment and 127 did not — or 24 percent sought treatment. Patients with genotypes 1 and 4 of the disease, which are less responsive to treatment, were less likely to initiate treatment, as were unmarried patients and patients with multiple diseases, or medical comorbidities.

The findings are published in the of Journal of Health Care for the Poor and Underserved.

http://www.upi.com/Health_News/2009/11/ … 257886770/

Hep c new treatment tested New Zealand

A recent news release about some successful hepatitis C   New Zealand Drug trial’s,  Interesting about US not allowing drug  trial within US, but ok for New Zealand and Australia etc

Hep c new treatment tested Wellington, Nov 6 NZPA - Researchers are claiming success in a New Zealand clinical trial of antiviral drugs used against the hepatitis C virus (HCV).

A combination of two experimental anti virals led to dramatic reductions in viral loads during the 13-day pilot trial, according to Edward Gane, of Auckland Clinical Studies.

Hepatitis C is a virus carried in the blood that can damage the liver, leading to cirrhosis (scarring), failure and cancer, and it has infected more than 30,000 New Zealanders.

The Food and Drug Administration (FDA) in the United States does not permit the illness to be treated without interferon- because of concerns such treatments could provoke resistance to drugs that might otherwise remain effective.

The drugs’ lead developer, Roche, said in a statement that phase two clinical trials would start early next year, though the studies must continue to be conducted outside the US because of the FDA policy on interferon.

Health Cheque

Been reading Health Cheque the truth we should all know about New Zealand’s public health system. A new book Gareth Morgan and Geoff Simmons

A great read about the New Zealand Health system, dissecting the subject well, what gets funded who gets treated; it’s well written and balanced in its approach.  Haven’t finished book yet but it is surprisingly readable, and insightful so far

Health Cheque link

NZ Needle exchange success

Thursday, 19 November, 2009 - 14:40 scoop link

Recent data has confirmed that New Zealand’s Needle Exchange Programme is one of the most successful in the world, but we could do even better, says Needle Exchange New Zealand National “Manager Charles Henderson.

He said, however, that a reduction in hepatitis C levels was the most pleasing result of all.

“Our 2004 study revealed that nearly three out of four New Zealand injecting drug users had been exposed to the hepatitis C virus. This year’s study indicates a significant drop in this statistic to around half.

Hepatitis C is a virus that can cause liver disease, leading to years of ill health and possibly even death. It can only be caught via the exchange of blood from an infected person. It is a significant risk for those drug users who share needles or other injecting paraphernalia.

The latest Household Drug Survey indicates 2 percent of New Zealanders inject or have injected drugs at some point in their lives, many of whom do so only occasionally or recreationally. This means 85,000 people are potentially susceptible to blood-borne viruses from drug use.” Charles Henderson

I   think needle exchanges are a good place to engage with active drug users with hepatitis C.  I think they are a key public health initiative New Zealand can be proud off. Lots of potential for preventative health savings in getting the needle exchange program working better and decreasing future spread of hepatitis C.

It is important to realise that the majority of people with hepatitis c don’t attend needle exchanges any more , Charles figures seem to suggest a 25% decrease in the numbers of people with hepatitis C attending  the needle exchange.

“The largest undiagnosed pool of people with HCV are likely to be those aged 40 – 60 years old, who were infected 25 – 40 years ago, who at that time occasionally (or even once) injected illicit drugs , but went on to lead ‘conventional lives’.  (Strategic Directions for Hepatitis C : Improving access to and uptake of hepatitis C treatment services.)

It seems that targeting hepatitis C education funding and programs to needle exchange programs misses the largest group of people with hepatitis C.   The needle exchange is a fantastic cost effective prevention and education program targeting active drug users not all people with Hepatitis c are active drug users.  Associating drug use and hepatitis C just builds and reinforces the stigma associated with Hepatitis C.

Jim Anderton MP made a great speech when opening the Christchurch needle exchange new location.

Anderton: Opening the new Rodger Wright Centre
Friday, 20 November 2009, 2:56 pm
Press Release: Progressive Party

“As a politician, I know that to make a difference to peoples’ lives, more often than not, means going the extra mile. I thank you for your commitment.

I wish we didn’t need this programme. I wish we didn’t have drug use causing the harm it does, wrecking the lives of many people, and wrecking many communities. But it does happen. It will keep happening.

And if we care about vulnerable victims then our responsibility is to reduce the harm to them as much as we can. The needle exchange programme does just that and I continue to support it for that reason.”

scoop here

Injecting, Infection, Illness: Abjection and Hepatitis C Stigma

Magdalena Harris

While Social Research has documented the prevalence and ill effects of Hepatitis C related stigma,

Magdalena discuses ways in which this stigmas is constituted

Three components central to hepatitis C stigma

1. illicit injecting

2. infectiousness and

3. societal aversion to chronic illness

Magdalena is a peer a great writer and world expert on Hepatitis C.  I always enjoy reading and learning from what she has to say, this contains some déjà vu moments where she has managed to capture the essence of many people’s experiences with Hepatitis C. Well worth a read.

Injecting, Infection, Illness: Abjection and Hepatitis C Stigma

Get tested campaign

Get tested campaign from UK  Words of wisdom from Topper Headon and others about getting treated  Get tested get treated now.

Get Tested! from Ross Aitken on Vimeo.

Have a great Holiday season

Best of health

www.hcv.org.nz

November 7, 2008

6th Australasian Viral Hepatitis Conference highlights and comments : Brisbane October 2008

christolakisbrisbane.jpg

Brisbane image by Christolakis

 

The 6th Australasian Viral Hepatitis Conference highlights and comments : Brisbane October 2008

This year there was a strong emphasis on hepatitis B, and the urgent call for a National Hepatitis B Strategy rang clearly across the three day meeting.

“almost 500 delegates ensured that this meeting was terrific event. “

“The conference was held back to back with the Australian Gastroenterology Week
meeting, which meant a good attendance of specialists.”

“The conference had a mix of epidemiology, community responses and
research and basic science. “

“It was a pretty dry conference with rather too much clinical stuff and little, it
appeared to me, of relevance to the situation in NZ. “

“It was a great conference though for catching up with lots of people - and I felt really
wiped out for a good few days afterwards. “

“well catered “

“great opportunity to catch up and share experiences”

Some key presentations

During the opening plenary, Stephen Locarnini, Head, Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia

gave a hypothetical scoop on how the media would respond if hep B were discovered in 2008: headlines like

“Killer Disease Impacts on 250 Million Globally” and
“2 Million Dead Every Year” –

A far cry from where things really are in 2008.  Mr Locarnini also suggested that one of the biggest barriers to
managing hepatitis B in Australia is, ironically, our reliance on the vaccination.
Jacqui Richmond spoke on her qualitative research, due to be released in May 2009. Some of her points of interest were:

  • 85% of respondents preferred face-to-face peer support
  • Peer educators required proactive training in the communication of Hepatitis C, as personal stories were not always representative
  • More education now leads to less stigma later
  • Fear, stigma and discrimination prevented people living with Hepatitis C from accessing treatment
  • 62% of the patients in the study diagnosed by their GP; of which only 49% were referred to a liver clinic for treatment
  • 50% of the respondents identified GPs as the worst providers of Hepatitis C information but 50% said GPs gave the best physical support.

Jacqui’s paper is to be published in May 2009.

Max Hopwood from the National Centre in HIV Social Research reported data from his qualitative research on ‘Post treatment outcomes’.Major themes of the study showed that clearing the infection minimized future illness, released people from stigma and improved quality of life.

However, there are potential long-term complications arising from treatment. Interview participants reported a variety of sustained physical and psychological after-effects from the Hepatitis C treatment. No end-of-treatment advice being given and treatment ending abruptly were both documented as problems. Participants also reported difficulty in coping with treatment after-effects, with a substantially reduced end-of-treatment quality of life. Some of the problems identified included cognitive difficulties, persistent neurotoxicity and immune system disorders.

Non-responders to Hepatitis C treatment reportedly mourn the loss of their future, the ‘loss of future memory’. Further, there is also the fear for their future health from hearing other people’s horror stories.

Alcohol use and Hepatitis C Everyday resistances: Safe to drink? Alcohol use and hepatitis C. Magdalena Harris, Fantastic peer presentation on the perspectives and peer experiences of alcohol and Hepatitis C

Matthews GV - Frequency of Rapid Virological Response and Its Utility as a Predictor of Treatment Outcome in Individuals Treated within the Australian Trial in Acute Hepatitis C (ATAHC) Rapid virological response (RVR) early in hep C treatment was widely shown to be a strong predictor of SVR (Sustained Virological Response, or cure).  This has implications for greater predictability of treatment success

A number of presentations strongly challenged the notion that all current drug users were inappropriate for hep C treatment, demonstrating that with appropriate support and screening, their success rate was comparable to any other group accessing treatment.

Prof Greg Dore reminded us that while there appears to have been a reduction in the notifications among 15-19 year olds (and evidence that testing patterns have stayed the same), the incidence of hep C in young
women under 20 has doubled.

More evidence was presented to remind us that hep C superinfection (or being infected with more than one genotype or strain of hep C) can and does happen to a significant proportion of people that have had multiple
exposures to hepatitis C.

Presentation - Tina Cooper

Supply and Demand: Strategies to Increase the Liver Donor Pool the paper talking about the need for more people to register as donors, held on the last day,
Presentation - Professor Ian Gust What if: Implementing a National Vaccination Program for HCV - Lessons Learnt from Other Strategies how close we are to having a working vaccine for HCV (also on the last day)
Keynote Speaker - Professor Ed Gane Issues with Liver Transplantation for Hepatitis C

Ed Gane’s talk of Liver Transplantation (especially how a liver will become HCV+ if given to an HCV+ patient)

…………………………………………………………………………………………………………………..

You can find a copy of  Alcohol use and Hepatitis C Everyday resistances: Safe to drink? Alcohol use and hepatitis C. Magdalena Harris, here

Thanks to the Daily Dose The World’s leading drug and alcohol news service for linking to this article about the issues we all face with our drinking choices and hepatitis C.  I highly recommend this daily dose of news.

Thanks to those who contributed info on conference additional feedback from conference attendees welcome email us your comments recommendations admin@hcv.org.nz or leave a comment below.

Its been a long week, im off to have my Roferon injection

best of health

www.hcv.org.nz

Powered by WordPress